Nanobiotix provides an update on its cash position and operating activity for the first quarter of 2026

▤ Summary

Nanobiotix reported its first-quarter 2026 operating progress and cash position, including 42.1 million euros in cash and cash equivalents at March 31, 2026. The company also said it completed a capital increase in May 2026 totaling about 86.1 million euros gross to help accelerate development of its platforms. It highlighted updated phase 2 data for JNJ-1900 (NBTXR3) in unresectable stage 3 non-small cell lung cancer, showing encouraging response rates and an acceptable safety profile. Nanobiotix also announced a protocol amendment in the ongoing NANORAY-312 phase 3 study and presented new preclinical Nanoprimer data at AACR 2026. Management said the recent financing should support working capital needs through 2029.

▦ Linked Companies